Patents by Inventor Steven Lockton

Steven Lockton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods, systems, and compositions for counting nucleic acid molecules
    Patent number: 11959129
    Abstract: Compositions and methods, systems, and kits for detecting and quantifying variations in numbers of molecules, particularly variations in gene dosage, e.g., due to gene duplication, or to variations from the normal euploid complement of chromosomes, e.g., trisomy of one or more chromosomes that are normally found in diploid pairs, without digital sequencing.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: April 16, 2024
    Assignee: Enumera Molecular, Inc.
    Inventors: Matthew Sekedat, Jeffrey Buis, Ronald David Beaubien, Jr., Sharat Singh, Jeff Perry, Steven Lockton, Chandni Jain, Natalie Mae Jameson-Kiesling
  • METHODS, SYSTEMS, AND COMPOSITIONS FOR COUNTING NUCLEIC ACID MOLECULES
    Publication number: 20220282315
    Abstract: Compositions and methods, systems, and kits for detecting and quantifying variations in numbers of molecules, particularly variations in gene dosage, e.g., due to gene duplication, or to variations from the normal euploid complement of chromosomes, e.g., trisomy of one or more chromosomes that are normally found in diploid pairs, without digital sequencing.
    Type: Application
    Filed: October 13, 2021
    Publication date: September 8, 2022
    Inventors: Matthew SEKEDAT, Jeffrey BUIS, Ronald David BEAUBIEN, JR., Sharat SINGH, Jeff PERRY, Steven LOCKTON, Chandni JAIN, Natalie Mae JAMESON-KIESLING
  • Methods, systems, and compositions for counting nucleic acid molecules
    Patent number: 11186863
    Abstract: Compositions and methods, systems, and kits for detecting and quantifying variations in numbers of molecules, particularly variations in gene dosage, e.g., due to gene duplication, or to variations from the normal euploid complement of chromosomes, e.g., trisomy of one or more chromosomes that are normally found in diploid pairs, without digital sequencing.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: November 30, 2021
    Assignee: Progenity, Inc.
    Inventors: Matthew Sekedat, Jeffrey Buis, Ronald David Beaubien, Jr., Sharat Singh, Jeff Perry, Steven Lockton, Chandni Jain, Natalie Mae Jameson-Kiesling
  • METHODS, SYSTEMS, AND COMPOSITIONS FOR COUNTING NUCLEIC ACID MOLECULES
    Publication number: 20210164029
    Abstract: Compositions and methods, systems, and kits for detecting and quantifying variations in numbers of molecules, particularly variations in gene dosage, e.g., due to gene duplication, or to variations from the normal euploid complement of chromosomes, e.g., trisomy of one or more chromosomes that are normally found in diploid pairs, without digital sequencing.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 3, 2021
    Inventors: Matthew Sekedat, Jeffrey Buis, Ronald David Beaubien, JR., Sharat Singh, Jeff Perry, Steven Lockton, Chandni Jain, Natalie Mae Jameson-Kiesling
  • Methods for predicting post-operative recurrence of Crohn's disease
    Patent number: 10697961
    Abstract: The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 30, 2020
    Assignees: Prometheus Biosciences, Inc., Katholieke Universiteit Leuven
    Inventors: Steven Lockton, Marc Ferrante, Severine Vermiere, Sharat Singh
  • Drug selection for non-small cell lung cancer therapy
    Patent number: 10640830
    Abstract: The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: May 5, 2020
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Sharat Singh, Phillip Kim, Steven Lockton
  • Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS
    Patent number: 10184940
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: January 22, 2019
    Assignee: Nestec S.A.
    Inventors: Sharat Singh, Nicholas Chi-Kwan Ling, Shui-Long Wang, Fred Princen, Stefan Westin, Steven Lockton
  • METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE
    Publication number: 20160334401
    Abstract: The present invention provides methods for predicting post-operative recurrence of Crohn's disease (CD) in a subject. With the present invention it is possible to predict whether a patient undergoing surgical treatment of CD is at risk of developing histological, radiographic, endoscopic, and/or clinical recurrence of the disease.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 17, 2016
    Applicants: NESTEC S.A., UNIVERSITY HOSPITALS LEUVEN
    Inventors: STEVEN LOCKTON, MARC FERRANTE, SEVERINE VERMIERE, SHARAT SINGH
  • DRUG SELECTION FOR NON-SMALL CELL LUNG CANCER THERAPY
    Publication number: 20160032403
    Abstract: The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
    Type: Application
    Filed: July 29, 2015
    Publication date: February 4, 2016
    Applicant: NESEC S.A,
    Inventors: Sharat Singh, Phillip Kim, Steven Lockton
  • ANTIBODIES TO MICROBIOME, STRESS FACTORS AND MAST CELL MARKERS AS DIAGNOSTIC MARKERS FOR IBS
    Publication number: 20150346200
    Abstract: The present invention provides methods for aiding in the diagnosis of irritable bowel syndrome (IBS) in an individual. In particular, the present invention is useful for determining whether a sample from an individual is an IBS sample or a healthy control sample using a statistical algorithm. Thus, the present invention provides an accurate diagnostic prediction of IBS and is useful for guiding treatment decisions.
    Type: Application
    Filed: March 30, 2015
    Publication date: December 3, 2015
    Applicant: NESTEC S.A.
    Inventors: SHARAT SINGH, Nicholas Chi-Kwan Ling, Shui-Long Wang, Fred Princen, Stefan Westin, Steven Lockton
  • METHODS FOR IMPROVING INFLAMMATORY BOWEL DISEASE DIAGNOSIS
    Publication number: 20150072879
    Abstract: The present invention provides methods and systems to predict and diagnose inflammatory bowel disease (IBD) and subtypes such as ulcerative colitis (UC) and Crohn's disease (CD) by detecting the presence, absence, level, and/or genotype of one or more sero-genetic-inflammation markers. Advantageously, with the present invention, it is possible to provide a diagnosis of IBD versus non-IBD, to rule out IBD that is inconclusive for CD and UC, and to differentiate between CD and UC with increased accuracy.
    Type: Application
    Filed: March 28, 2014
    Publication date: March 12, 2015
    Applicant: NESTEC S.A.
    Inventors: Fred Princen, Steven Lockton, Lisa J. Croner, Frederick A. Fletcher, Thomas Stockfisch, Sharat Singh
  • Methods for improving inflammatory bowel disease diagnosis
    Patent number: 8715943
    Abstract: The present invention provides methods and systems to predict and diagnose inflammatory bowel disease (IBD) and subtypes such as ulcerative colitis (UC) and Crohn's disease (CD) by detecting the presence, absence, level, and/or genotype of one or more sero-genetic-inflammation markers. Advantageously, with the present invention, it is possible to provide a diagnosis of IBD versus non-IBD, to rule out IBD that is inconclusive for CD and UC, and to differentiate between CD and UC with increased accuracy.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 6, 2014
    Assignee: Nestec S.A.
    Inventors: Fred Princen, Steven Lockton, Lisa J. Croner, Frederick A. Fletcher, Thomas Stockfisch, Sharat Singh